CureVac NV (CVAC) Options

$3.15 + 12% MRNA lawsuit could make them some cash. Patent valid 

CVAC IN HERE...WHAT A BALANCE SHEET

CVAC under $4

There is a cure again

CVAC new 52 week low

CVAC new 52 week low

CVAC new 52 week low

CVAC new 52 week low

https://www.otcmarkets.com/stock/CVAC

https://www.otcmarkets.com/stock/CVAC

https://www.otcmarkets.com/stock/CVAC

https://www.otcmarkets.com/stock/CVAC

https://www.otcmarkets.com/stock/CVAC

CVAC
CureVac NV
8.99
0.09 (1.01%)
Volume: 232,857
Day Range: 8.73 - 9.15
Last Trade Time: 6:30:54 PM EDT

Big News coming soon... just be patient....

CVAC
CureVac NV
10.98
1.30 (13.43%)
Volume: 464,848
Day Range: 9.72 - 10.47
Last Trade Time: 7:53:28 PM EDT

CVAC
CureVac NV
10.98
1.30 (13.43%)
Volume: 464,848
Day Range: 9.72 - 10.47
Last Trade Time: 7:53:28 PM EDT

CVAC
CureVac NV
10.98
1.30 (13.43%)
Volume: 464,848
Day Range: 9.72 - 10.47
Last Trade Time: 7:53:28 PM EDT

CVAC
CureVac NV
12.23
0.80 (7.00%)
Volume: 2,433,695
Day Range: 11.02 - 12.36
Last Trade Time: 7:59:28 PM EDT

CVAC
CureVac NV
12.23
0.80 (7.00%)
Volume: 2,433,695
Day Range: 11.02 - 12.36
Last Trade Time: 7:59:28 PM EDT

CVAC
CureVac NV
9.15
-0.28 (-2.97%)
Volume: 373,244
Day Range: 9.06 - 9.49
Last Trade Time: 6:38:15 PM EDT

CVAC
CureVac NV
7.37
0.05 (0.68%)
Volume: 613,302
Day Range: 7.28 - 7.40
Last Trade Time: 7:50:44 PM EDT

CVAC
CureVac NV
7.79
-0.11 (-1.39%)
Volume: 227,150
Day Range: 7.66 - 8.13
Last Trade Time: 5:09:42 PM EDT

CVAC
CureVac NV
7.79
-0.11 (-1.39%)
Volume: 227,150
Day Range: 7.66 - 8.13
Last Trade Time: 5:09:42 PM EDT

CVAC
CureVac NV
7.79
-0.11 (-1.39%)
Volume: 227,150
Day Range: 7.66 - 8.13
Last Trade Time: 5:09:42 PM EDT

CVAC
CureVac NV
7.79
-0.11 (-1.39%)
Volume: 227,150
Day Range: 7.66 - 8.13
Last Trade Time: 5:09:42 PM EDT

CVAC
CureVac NV
8.50
-0.16 (-1.85%)
Volume: 641,450
Day Range: 8.52 - 8.68
Last Trade Time: 7:00:46 PM EST

CVAC
CureVac NV
11.06
-0.62 (-5.31%)
Volume: 537,147
Day Range: 11.01 - 11.83
Last Trade Time: 7:55:22 PM EST

it is relative CureVac (CVAC) Receives a Buy from Berenberg Bank
August 23 2022 - 09:55PM
TipRanks
Alert
Print
Share On Facebook
In a report released yesterday, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on CureVac (CVAC - Research Report), with a price target of $45.00. The company's shares closed yesterday at $11.32.Shu covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arcus Biosciences, and Sutro Biopharma. According to TipRanks, Shu has an average return of -21.0% and a 23.78% success rate on recommended stocks. Currently, the analyst consensus on CureVac is a Moderate Buy with an average price target of $28.50, implying a 151.77% upside from current levels.
https://www.tipranks.com/news/blurbs/curevac-cvac-receives-a-buy-from-berenberg-bank?utm_source=advfn.com&utm_medium=referral

CVAC
CureVac NV
6.60
-0.21 (-3.08%)
Volume: 387,429
Day Range: 6.58 - 6.99
Last Trade Time: 4:09:13 PM EST

i think $CVAC is ah buyout candidate /\

let's say $40

CVAC
CureVac NV
6.81
0.04 (0.59%)
Volume: 1,065,479
Day Range: 6.52 - 6.93
Last Trade Time: 4:46:47 PM EST

CVAC
CureVac NV
7.49
0.28 (3.88%)
Volume: 181,787
Day Range: 7.155 - 7.49
Bid: 6.13
Ask: 9.18
Last Trade Time: 4:13:18 PM EDT
Total Trades: 1,819
CVAC Detailed Quote

CVAC
CureVac NV
7.49
0.28 (3.88%)
Volume: 181,787
Day Range: 7.155 - 7.49
Bid: 6.13
Ask: 9.18
Last Trade Time: 4:13:18 PM EDT
Total Trades: 1,819
CVAC Detailed Quote

CVAC
CureVac N.V.
Ordinary Shares
9.84
-0.40

-3.90%

Delayed (15 Min) Trade Data: 04:00pm 08/31/2022
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research

we don't show quote ?????

we don't show quote ?????

CureVac (CVAC) Receives a Buy from Berenberg Bank
August 23 2022 - 09:55PM
TipRanks
Alert
Print
Share On Facebook
In a report released yesterday, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on CureVac (CVAC - Research Report), with a price target of $45.00. The company's shares closed yesterday at $11.32.Shu covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arcus Biosciences, and Sutro Biopharma. According to TipRanks, Shu has an average return of -21.0% and a 23.78% success rate on recommended stocks. Currently, the analyst consensus on CureVac is a Moderate Buy with an average price target of $28.50, implying a 151.77% upside from current levels.
https://www.tipranks.com/news/blurbs/curevac-cvac-receives-a-buy-from-berenberg-bank?utm_source=advfn.com&utm_medium=referral

CVAC
CureVac NV
12.62
-0.03 (-0.24%)
Volume: 276,718
Day Range: 12.39 - 12.79
Bid: 12.60
Ask: 13.18
Last Trade Time: 4:57:18 PM EDT
Total Trades: 3,775
CVAC Detailed Quote

Interesting new Beneficial Owners recently. Taken an entry position today.
Looks like Covid-19 vaccines still hold prominent place in biotech research: "CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work." https://finance.yahoo.com/news/1-curevac-gsks-experimental-covid-124419805.html

CureVac NV (CVAC)
18.18 ? -0.65 (-3.45%)
Volume: 402,327 @06/03/22 6:58:05 PM EDT
Bid Ask Day's Range
17.61 20.1 17.56 - 18.58
CVAC Detailed Quote

CureVac NV (CVAC)
18.18 ? -0.65 (-3.45%)
Volume: 402,327 @06/03/22 6:58:05 PM EDT
Bid Ask Day's Range
17.61 20.1 17.56 - 18.58
CVAC Detailed Quote

https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-contrafect-cfrx-curevac-cvac?utm_source=advfn.com&utm_medium=referral

https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-contrafect-cfrx-curevac-cvac?utm_source=advfn.com&utm_medium=referral

CureVac NV (CVAC)
17.205 ? 0.625 (3.77%)
Volume: 164,845 @04/29/22 1:27:43 PM EDT
Bid Ask Day's Range
17.2 17.25 16.47 - 17.44
CVAC Detailed Quote

CureVac NV (CVAC)
15.69 ? -1.08 (-6.44%)
Volume: 305,719 @03/11/22 5:11:50 PM EST
Bid Ask Day's Range
15.7 16.66 15.68 - 17.225
CVAC Detailed Quote

CureVac NV (CVAC)
18.19 ? 0.05 (0.28%)
Volume: 587,579 @02/04/22 5:09:58 PM EST
Bid Ask Day's Range
17.05 19.74 17.7685 - 18.61
CVAC Detailed Quote

https://www.otcmarkets.com/stock/CVAC

https://www.otcmarkets.com/stock/CVAC

CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2CoV 'Highly Comparable' With Pfizer's mRNA Vaccine
MT NEWSWIRES 3:11 PM ET 11/18/2021

03:11 PM EST, 11/18/2021 (MT Newswires) -- CureVac(CVAC) said Thursday the extended preclinical study of the second-generation vaccine candidate, CV2CoV, showed that neutralizing antibody levels after full vaccination of animals were "highly comparable" with Pfizer (PFE) and BioNTech's (BNTX) licensed mRNA vaccine, Comirnaty.

CureVac (CVAC) is developing CV2CoV in partnership with GlaxoSmithKline (GSK). Animals were vaccinated with either 12 micrograms of CV2CoV or a 30 microgram standard dose of Comirnaty.

Data showed that targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model.